DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jeong, Hye Won | ko |
dc.contributor.author | Kim, Se-Mi | ko |
dc.contributor.author | Jung, Min Kyung | ko |
dc.contributor.author | Noh, Ji Yun | ko |
dc.contributor.author | Yoo, Ji-Seung | ko |
dc.contributor.author | Kim, Eun-Ha | ko |
dc.contributor.author | Kim, Young-Il | ko |
dc.contributor.author | Yu, Kwangmin | ko |
dc.contributor.author | Jang, Seung-Gyu | ko |
dc.contributor.author | Gil, Juryeon | ko |
dc.contributor.author | Casel, Mark Anthony | ko |
dc.contributor.author | Rare, Rollon | ko |
dc.contributor.author | Choi, Jeong Ho | ko |
dc.contributor.author | Kim, Hee-Sung | ko |
dc.contributor.author | Kim, Jun Hyoung | ko |
dc.contributor.author | Um, Jihye | ko |
dc.contributor.author | Kim, Chaeyoon | ko |
dc.contributor.author | Kim, Yeonjae | ko |
dc.contributor.author | Chin, Bum Sik | ko |
dc.contributor.author | Jung, Sungmin | ko |
dc.contributor.author | Choi, Jun Yong | ko |
dc.contributor.author | Song, Kyoung-Ho | ko |
dc.contributor.author | Kim, Yong-Dae | ko |
dc.contributor.author | Park, Jun-Sun | ko |
dc.contributor.author | Song, Joon Young | ko |
dc.contributor.author | Shin, Eui-Cheol | ko |
dc.contributor.author | Choi, Young Ki | ko |
dc.date.accessioned | 2022-12-21T09:01:11Z | - |
dc.date.available | 2022-12-21T09:01:11Z | - |
dc.date.created | 2022-12-21 | - |
dc.date.created | 2022-12-21 | - |
dc.date.created | 2022-12-21 | - |
dc.date.created | 2022-12-21 | - |
dc.date.issued | 2022-10 | - |
dc.identifier.citation | CELL REPORTS MEDICINE, v.3, no.10 | - |
dc.identifier.issn | 2666-3791 | - |
dc.identifier.uri | http://hdl.handle.net/10203/303452 | - |
dc.description.abstract | Omicron has become the globally dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, creating additional challenges due to its ability to evade neutralization. Here, we report that neutralizing antibodies against Omicron variants are undetected following COVID-19 infection with ancestral or past SARS-CoV-2 variant viruses or after two-dose mRNA vaccination. Compared with two-dose vaccination, a three-dose vaccination course induces broad neutralizing antibody responses with improved durability against different SARS-CoV-2 variants, although neutralizing antibody titers against Omicron remain low. Intriguingly, among individuals with three-dose vaccination, Omicron breakthrough infection substantially augments serum neutralizing activity against a broad spectrum of SARS-CoV-2 variants, including Omicron variants BA.1, BA.2, and BA.5. Additionally, after Omicron breakthrough infection, memory T cells respond to the spike proteins of both ancestral and Omicron SARS-CoV-2 by producing cytokines with polyfunctionality. These results suggest that Omicron breakthrough infection following three-dose mRNA vaccination induces pan-SARS-CoV-2 immunity that may protect against emerging SARS-CoV-2 variants of concern. © 2022 The Author(s) | - |
dc.language | English | - |
dc.publisher | ELSEVIER | - |
dc.title | Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection | - |
dc.type | Article | - |
dc.identifier.wosid | 000917310900002 | - |
dc.identifier.scopusid | 2-s2.0-85139299618 | - |
dc.type.rims | ART | - |
dc.citation.volume | 3 | - |
dc.citation.issue | 10 | - |
dc.citation.publicationname | CELL REPORTS MEDICINE | - |
dc.identifier.doi | 10.1016/j.xcrm.2022.100764 | - |
dc.contributor.localauthor | Shin, Eui-Cheol | - |
dc.contributor.nonIdAuthor | Jeong, Hye Won | - |
dc.contributor.nonIdAuthor | Kim, Se-Mi | - |
dc.contributor.nonIdAuthor | Jung, Min Kyung | - |
dc.contributor.nonIdAuthor | Noh, Ji Yun | - |
dc.contributor.nonIdAuthor | Yoo, Ji-Seung | - |
dc.contributor.nonIdAuthor | Kim, Eun-Ha | - |
dc.contributor.nonIdAuthor | Kim, Young-Il | - |
dc.contributor.nonIdAuthor | Yu, Kwangmin | - |
dc.contributor.nonIdAuthor | Jang, Seung-Gyu | - |
dc.contributor.nonIdAuthor | Gil, Juryeon | - |
dc.contributor.nonIdAuthor | Casel, Mark Anthony | - |
dc.contributor.nonIdAuthor | Rare, Rollon | - |
dc.contributor.nonIdAuthor | Choi, Jeong Ho | - |
dc.contributor.nonIdAuthor | Kim, Hee-Sung | - |
dc.contributor.nonIdAuthor | Kim, Jun Hyoung | - |
dc.contributor.nonIdAuthor | Um, Jihye | - |
dc.contributor.nonIdAuthor | Kim, Chaeyoon | - |
dc.contributor.nonIdAuthor | Kim, Yeonjae | - |
dc.contributor.nonIdAuthor | Chin, Bum Sik | - |
dc.contributor.nonIdAuthor | Choi, Jun Yong | - |
dc.contributor.nonIdAuthor | Song, Kyoung-Ho | - |
dc.contributor.nonIdAuthor | Kim, Yong-Dae | - |
dc.contributor.nonIdAuthor | Park, Jun-Sun | - |
dc.contributor.nonIdAuthor | Song, Joon Young | - |
dc.contributor.nonIdAuthor | Choi, Young Ki | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | ancestral | - |
dc.subject.keywordAuthor | breakthrough infection | - |
dc.subject.keywordAuthor | cross-neutralization | - |
dc.subject.keywordAuthor | D614G | - |
dc.subject.keywordAuthor | mRNA vaccine | - |
dc.subject.keywordAuthor | Omicron BA.1 | - |
dc.subject.keywordAuthor | Omicron BA.2 | - |
dc.subject.keywordAuthor | recovered patient | - |
dc.subject.keywordAuthor | SARS-CoV-2 | - |
dc.subject.keywordAuthor | T cell immune response | - |
dc.subject.keywordAuthor | variants of concern | - |
dc.subject.keywordPlus | NEUTRALIZING ANTIBODIES | - |
dc.subject.keywordPlus | SARS-COV-2 | - |
dc.subject.keywordPlus | IMMUNITY | - |
dc.subject.keywordPlus | MATURATION | - |
dc.subject.keywordPlus | BREADTH | - |
dc.subject.keywordPlus | POTENCY | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.